We administered recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) (120 pg/m*/d by continuous intravenous [IV] infusion) to 12 patients with newly diagnosed acute myeloid leukemia (AML) at relatively high risk of early death during remission induction. GM-CSF began 3 days after completion of induction chemotherapy (ara-C 1.5 g/m2 d x 4 days by continuous IV infusion after a 3 g/m2 bolus). Rates of fatal infection (42%). pneumonia and/or sepsis (83%). and CR (50%) did not differ significantly ( P < .05) from those observed after administration of the identical chemotherapy without GM-CSF to 53 historical controls with newly diagnosed AML at similarly high risk of early death. There were no significant differences between the GM-CSF-treated and the historical EUTROPENIA after chemotherapy of acute myeloid
EUTROPENIA after chemotherapy of acute myeloid N leukemia (AML) is associated with infections that often are the cause of death in elderly patients during remission induction.',2 Use of granulocyte-macrophage colony-stimulating factor (GM-CSF)' might shorten the duration of neutropenia after chemotherapy, given observations that GM-CSF can increase neutrophil counts in patients with acquired immunodeficiency syndrome (AIDS),4 solid tumor^,^ aplastic anemia,6 and myelodysplastic syndromes.6-8
However, use of GM-CSF for this purpose in AML is not without risk, given indications that myeloid leukemia cells in culture can use GM-CSF as a growth factor,'.'' and that its use in patients with refractory anemia with excess blasts (RAEB) or excess blasts in transformation (RAEBT) has been associated with disease acceleration.' Therefore, in this study we administered GM-CSF only to patients we considered at relatively high risk of early death, primarily from infection, during remission induction. GM-CSF was administered only after completion of induction chemotherapy because of our anxieties that earlier administration of the growth factor might stimulate production of myeloblasts rather than neutrophils.
PATIENTS AND METHODS
Twelve consecutive patients with newly diagnosed AML and with greater than 10% predicted probability of dying during the 28 days after initiation of chemotherapy, as judged by a published logistic regression model," were treated. Ten percent has been the median value in previous patients, with the group with values above 10% having a 30% 28-day mortality rate, a 40% overall induction mortality rate (with mortality primarily due to infection), and only a 45% C R rate after treatment with anthracyclines or amacrine plus conventional dose ara-C, or high-dose ara-C alone. As can be seen in Table 1 , the median age was 62 years, and a quarter of the patients were primarily bedridden before therapy (Zubrod performance status of 2 3 ) . One patient had staphylococcal septicemia when therapy began, while another had pneumonia. Chemotherapy consisted of ara-C 6 g/m2 by continuous intravenous (IV) infusion over 96 hours, with a 3 g/m2 bolus administered 12 hours before the start of the infusion. Recombinant human GM-CSF was supplied by Schering-Plough/Sandoz Corp, Kenilworth, NJ. This GM-CSF, synthesized in Escherichia coli, is not glycosylated. GM-CSF was administered at a dose of 120 pg/m2/d by continuous IV infusion beginning 3 days after completion of ara-C. Bone marrows were not systematically examined immediately before GM-CSF administration, but were regularly examined weekly thereafter. GM-CSF was to continue until the circulating neutrophil count, checked daily, was 2 1,00O/pL. Patients achieving C R (4% blasts in the marrow, >1,000 neutrophils, and >100,000 platelets/pL) received postremission therapy with ara-C, but without further GM-CSF.
We compared remission rates, infection rates, and days needed after initiation of chemotherapy to attain 500 or 1,000 neutrophils/ pL or 50,000 or 100,000 platelets/pL in study patients with results obtained in historical controls. These were all the 53 patients with newly diagnosed AML, and with predicted 28-day mortality probabilities greater than 10% treated with the same dose and schedule of ara-C given without GM-CSF during a 1985 to 1988 trial. The median predicted probability of 28-day mortality was 36% in the ara-C + GM-CSF patients, and 26% in the historical controls. The two groups were similar with regard to age, performance status, and karyotype. The chi-square test was used to compare rates in the two groups. Gehan's modification of the generalized Wilcoxon test was used to compare the percent of patients in the two groups who had 500 or 1,000 neutrophils/pL or 50,000 or 100,000 platelets/pL by days 1, 2, 3, 4, 5, etc, after beginning ara-C with patients dying or changed to alternative therapy before attaining the count in question censored at the time of death, or initiation of alternative therapy. Because we felt that GM-CSF might increase neutrophil counts more in patients whose leukemia responded to chemotherapy than in nonrespnding patients, we did similar comparisons using only the subsets of patients in the study and historical groups who entered CR. A P value of <.05 was considered significant. Table 2 , complete remissions occurred in 6 of the 12 patients. Patients 1 through 5 required 1 course of treatment to enter CR, and patient 6 required 2 courses. The 50% CR rate compares with a rate of 53% in the historical controls (P = not significant [NS]), while the 42% of patients in CR after 1 course compares with 34% in the controls (P = NS). Pretreatment cytogenetic abnormalities disappeared in remission in patients 2, 4, and 6, but +8 persisted in patient 3, whose remission lasted only 8 weeks. Patients 5 and 6 also had brief remissions. Table 2 also illustrates that four patients died of infection during remission induction. These deaths occurred between 13 and 20 days after beginning chemotherapy, at which times all four patients had tlOO neutrophils/bL, with bone marrows in three showing marked hypoplasia (not examined in the fourth patient, who died 13 days after beginning chemotherapy). In addition, patient 2 died of pneumonia while in CR. Beside the five patients that died of infection, five other patients developed pneumonia and/or sepsis. These infections occurred when the neutrophil count was t200/pL and resolved coincident with return of the count toward normal. The fatal infection rate (5 of 12) compares with a rate of 17 of 53 in the historical controls (P = NS), while the overall rate of pneumonia and/or sepsis (10 of 12) compares with a rate of 37 of 53 in the controls (P = NS).
RESULTS

As seen in
Among the eight patients who survived long enough for anti-leukemia response to induction therapy to be fully evaluated (patients 1 through 8), unequivocal evidence of disease progression after initiation of GM-CSF occurred only in patient 8. This patient, the only one treated for promyelocytic leukemia, had 9% promyelocytes in a 5% cellular marrow immediately before beginning GM-CSF, and 80% promyelocytes in a 90% cellular marrow after 1 week of GM-CSF. Disseminated intravascular coagulation was present. Daunorubicin without GM-CSF was administered and C R occurred.
The time required to attain a neutrophil count of 1 ,OOO/pL karied considerably (Table 2) , and there was similar variation in time to 500 neutrophils/pL. Seventeen and 18 days were the minimums required to reach these counts, respectively. No patient who entered C R required continued administration of GM-CSF to maintain a normal neutrophil count, although such GM-CSF dependence did occur in patient 7, despite the presence of a normal marrow differential after chemotherapy. There were no significant differences in the days required to reach neutrophil counts of 1,000 or 500/pL between either the 12 ara-C + GM-CSF treated study patients and the 53 ara-C treated historical controls, or between the subsets of these two groups that entered CR. Table 2 also illustrates considerable variation in days to 100,000 platelets/pL, and comparisons similar to those undertaken for neutrophil recovery failed to show significant differences between ara-C + GM-CSF treated patients and ara-C treated historical controls in the days required to reach platelet counts of either 100,000 or 50,OOO/pL.
Toxicity forced discontinuation of GM-CSF in patient 1, who developed evidence of the capillary-leak syndrome that resolved once GM-CSF was discontinued. While three other patients developed fluid retention, it was impossible to ascertain if this resulted from GM-CSF or from intercurrent medical problems.
DISCUSSION
Our results fail to provide evidence that GM-CSF, as administered in this study, was beneficial to our patients. Most importantly, the fatal infection rate was high and not statistically different than that seen in a similarly poorprognosis historical control group. The rate of pneumonia and/or sepsis was also very high and similar to that seen in the historical controls, and there was no improvement in the CR rate (50% v 53%). We also could not demonstrate that GM-CSF accelerated neutrophil recovery.
Several points must be kept in mind. We treated only 12 patients, obviously limiting our ability to detect all but the most obvious improvements. Buechner et all2 reported that elderly patients with newly diagnosed AML treated with GM-CSF after administration of daunorubicin, ara-C, and 6 TG (TAD-9) required a median of 5 fewer days to achieve 500 neutrophilslpul than historical controls treated with TAD-9 without GM-CSF, although no comparisons between infection rates or remission rates were reported. Our timing of GM-CSF administration, which only began 3 days after completion of chemotherapy, may have been suboptimal. Earlier administration of GM-CSF may have produced earlier neutrophil recovery. In particular, the observation that patients 9 through 12 died of infection before they could realistically benefit from the earliest recovery in neutrophil count as observed in patients who entered C R suggests that GM-CSF may have been administered too late to detect a clinical benefit, at least in these poor-prognosis patients. Fear of stimulating growth of leukemia led to our initial reluctance to administer GM-CSF earlier than we did. However, disease progression after use of GM-CSF was apparent in only one patient, and regrowth of leukemia in this patient, who had promyelocytic leukemia, may have reflected omission of an anthracycline. It should be pointed out that 4 of our 12 patients died before anti-leukemia response could be fully evaluated. Furthermore, the relatively brief remissions observed in three of our patients may have reflected an antagonistic effect of GM-CSF on the anti-leukemia action of ara-C. Nonetheless, the rarity with which GM-CSF seemed to promote growth of leukemia as judged by outcome of remission induction therapy suggests that it might be safe to undertake larger, randomized studies, perhaps using earlier administration of GM-CSF, to definitely determine the role of GM-CSF added to chemotherapy in patients with newly diagnosed AML.
